This oral formulation of topotecan was approved on October 12, 2007, for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response who are ≥45 days from the end of first-line chemotherapy.
Topotecan is a semisynthetic derivative of camptothecin; this antitumor agent acts as a topoisomerase I inhibitor, thus causing double-strand DNA damage during DNA synthesis. This oral formulation of topotecan was approved on October 12, 2007, for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response who are ≥45 days from the end of first-line chemotherapy.
Efficacy. The efficacy of this agent was evaluated in a randomized, comparative, open-label trial in patients with relapsed SCLC who were prior responders to first-line chemotherapy, were not considered candidates for standard intravenous (IV) chemotherapy, and had relapsed $45 days from the end of first-line chemotherapy. Patients were randomized to oral topotecan 2.3 mg/m2 /d for 5 consecutive days, repeated every 21 days, plus best supportive care (BSC) (n=71) or to BSC alone (n=70). The primary end point in the study was overall survival. Patients treated with oral topotecan plus BSC received a median of 4 treatment courses, with a median topotecan dose intensity of 3.77 mg/m2/wk. Patients treated with topotecan plus BSC demonstrated a statistically significant improvement in overall survival (25.9 wk; 95% CI, 18.3–31.6) compared with patients treated with BSC alone (13.9 wk; 95% CI, 11.1–18.6; HR=0.64; 95% CI, 0.45–0.90; log-rank P=.0104).
Safety. Bone marrow suppression (primarily manifested as neutropenia) is a dose-limiting toxicity of topotecan treatment. Topotecan-induced neutro-penia can also lead to neutropenic colitis; fatalities caused by neutropenic colitis have been reported in topotecan-treated patients. Topotecan should be administered only to patients with adequate bone marrow reserves, and patients' peripheral blood cell counts should be closely monitored during treatment. Severe diarrhea has been reported in patients treated with oral topotecan; this treatment-related diarrhea is associated with significant morbidity and should therefore be aggressively managed. This agent may cause fetal harm in pregnant women. The most common adverse events reported in association with topotecan treatment include anemia, leukopenia, neutropenia, thrombocytopenia, nausea, diarrhea, vomiting, alopecia, fatigue, anorexia, asthenia, and pyrexia.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More